“This CFDA clearance is a significant milestone achievement for SpineCraft and further advances our strategy to establish SpineCraft as a true global spine company.” said SpineCraft CEO Wagdy Asaad, MD.
The China spine market has become the second most important after the USA and is projected to be worth over $1 billion by 2019. This is driven by China’s large population, rising standard of living, improving treatment options and growing ageing population; all signal significant room for growth.
To learn more about SpineCraft, click here.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
